Human Genome Sciences licenses gene sequences to Pfizer.Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. , Inc. (Rockville, MD) signed a license agreement with Pfizer, Inc. (New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY) under which Pfizer has acquired non-exclusive worldwide rights to research, develop and commercialize products based on gene sequences from Staphylococcus aureus Staphylococcus au·re·us n. A bacterium that causes furunculosis, pyemia, osteomyelitis, suppuration of wounds, and food poisoning. Staphylococcus aureus Staphylococcus pyogenes , for potential human and animal use. The agreement amends AMENDS. A satisfaction, given by a wrong doer to the party injured for a wrong committed. 1 Lilly's Reg. 81. 2. By statute 24 Geo. II. c. 44, in England, and by similar statutes in some of the United States, justices of the peace, upon being notified of an a 1996 agreement with Pharmacia & Upjohn, Inc., which was acquired by Pfizer in early 2003. Human Genome Sciences will receive from Pfizer a one-time license fee of an undisclosed amount under the terms of the amended agreement, and Pfizer is relieved of any other obligation under the prior agreement. Human Genome Sciences, Inc. +1-301-315-2777 www.hgsi.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion